Objectives Rituximab (RTX) may favorably affect lung function and skin fibrosis in patients
with systemic sclerosis (SSc). We aimed to assess long-term efficacy and safety of RTX in SSc …

… Author links open overlay panel Irini Flouri MD a , Theodora E. Markatseli MD b , Paraskevi
V. Voulgari MD b , Kyriaki A. Boki MD c , Ioannis Papadopoulos MD d , Loukas Settas MD …

Objectives The spondyloarthritides (SpA) are associated with an increased cardiovascular
risk. We studied cardiovascular risk factors in patients with SpA. Methods The following risk …

Objective: To describe granuloma annulare (GA) skin lesion development in patients during
anti-tumour necrosis factor (TNF) therapy. Methods: 199 patients with rheumatoid arthritis …

Objective. To evaluate the 10-year drug survival of the first tumor necrosis factor inhibitor (TNFi)
administered to patients with spondyloarthritis (SpA) overall and comparatively between …

The use of biologic medications has represented a great advancement in the treatment of
autoimmune rheumatic diseases. Despite their excellent efficacy, during the last years, a …

OBJECTIVES: The majority of patients with ankylosing spondylitis (AS) and psoriatic arthritis
(PsA) are affected during their peak reproductive years. Tumor necrosis factor (TNF)α plays …

Psoriatic arthritis (PsA) is a specific form of inflammatory arthritis associated with skin psoriasis.
PsA makes part of a heterogeneous group of arthritides called the spondyloarthropathies…

Objective. To describe the longterm clinical and radiological outcomes in rheumatoid arthritis
(RA) in a cohort in northwestern Greece; and to investigate predictive factors of radiological …

OBJECTIVE:: To investigate the efficacy, toxicity, and drug discontinuation in patients with
psoriatic arthritis treated with anti-tumor necrosis factor agents. METHODS:: Sixty-five patients …